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Abstract
Anthrax toxin is the major virulence factor produced by Bacillus anthracis. The toxin consists of three protein subunits:
protective antigen (PA), lethal factor, and edema factor. Inhibition of PA binding to its receptors, tumor endothelium
marker-8 (TEM8) and capillary morphogenesis protein-2 (CMG2) can effectively block anthrax intoxication, which is
particularly valuable when the toxin has already been overproduced at the late stage of anthrax infection, thus rendering
antibiotics ineffectual. Receptor-like agonists, such as the mammalian cell-expressed von Willebrand factor type A (vWA)
domain of CMG2 (sCMG2), have demonstrated potency against the anthrax toxin. However, the soluble vWA domain of
TEM8 (sTEM8) was ruled out as an anthrax toxin inhibitor candidate due to its inferior affinity to PA. In the present study, we
report that L56A, a PA-binding-affinity-elevated mutant of sTEM8, could inhibit anthrax intoxication as effectively as sCMG2
in Fisher 344 rats. Additionally, pharmacokinetics showed that L56A and sTEM8 exhibit advantages over sCMG2 with better
lung-targeting and longer plasma retention time, which may contribute to their enhanced protective ability in vivo. Our
results suggest that receptor decoys based on TEM8 are promising anthrax toxin inhibitors and, together with the
pharmacokinetic studies in this report, may contribute to the development of novel anthrax drugs.
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Introduction
Anthrax toxin is the major virulence factor produced by Bacillus
anthracis and consists of three protein subunits: protective antigen
(PA), lethal factor (LF), and edema factor (EF). This toxin enters
the cell cytoplasm and exerts toxic effects in a PA-mediated
manner. More specifically, PA binds to cell surface receptors,
forming a pre-pore complex after activation by furin at the cell
membrane, followed by the binding of up to three molecules of LF
and/or EF to the complex [1]. The entire complex is then
internalized by receptor-mediated endocytosis [2]. Acidification in
the endosome promotes transformation of the pre-pore complex
into the pore complex and translocation of the catalytic LF and/or
EF molecules into the cell cytosol.
The anthrax toxin receptors, tumor endothelium marker-8
(TEM8) [3] and capillary morphogenesis protein-2 (CMG2) [4],
are type one transmembrane proteins that contain an extracellular
von Willebrand factor type A (vWA) domain , which has been well
established as the domain that directly interacts with PA [3,4].
Other parts of the extracellular and transmembrane regions are
necessary for anthrax intoxication, but the cytoplasmic region does
not seem to be required [5]. However, cytoplasmic tails could
regulate the vWA domain’s affinity for PA binding and are
important for efficient toxin uptake [2,6,7]. The highly conserved
MIDAS motif in the vWA domain has been shown to be the key site
for metal ion-dependent interactions with PA D683 [8]. Although
their vWA domains share 60% identical residues, the two receptors
significantly differ in their binding to PA: the 153–154 site, residing
in the b4-a4 loop of CMG2, presents an additional interaction with
PA domain 2 that does not occur with TEM8 [9].
Inhibition of PA binding to cell receptors has proven to be an
effective therapy for anthrax intoxication. In addition to antibodies
[10] and polyvalent molecules [11] targeted to the binding sites of
PA or its receptors, soluble fragments of receptors, such as the
mammalian cell-expressed vWA domain of CMG2 (sCMG2),
have also been reported to inhibit PA-receptor binding [12].
Moreover, antibody Fc fragments have been fused to sCMG2,
which efficiently improved their plasma residence time and
preserved their affinity [13,14]. Furthermore, the ability of
sCMG2 to block antibody-resistant forms of anthrax toxin and
relevant bacterial strains has been validated [13]. In addition, a
new plant expression system has been built for producing Fc-fused
CMG2 [14,15]. However, because of its lower affinity, the vWA
domain of TEM8 (sTEM8) was ruled out from the first antitoxin
design [12]. Thus far, TEM8 in Fc fusion form has only been
applied as an antitumor decoy [16].
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residue in sTEM8 with the homologous alanine residue found in
sCMG2 (referenced as L56A) could improve the antitoxin efficacy
of sTEM8 in a cell-based anthrax toxin neutralization assay [17].
In the current study, we confirm the elevated affinity of L56A to
PA and demonstrate its potency as a toxin inhibitor in rats.
Pharmacokinetic studies were performed to compare the behaviors
of sTEM8, L56A, and sCMG2 in vivo. The results demonstrate the
advantages of sTEM8-based constructs over sCMG2 as anthrax
toxin inhibitors.
Results
sTEM8 and its mutant L56A exhibit lower PA binding
affinities than sCMG2
In our previous work [17], we demonstrated that the sTEM8
mutant L56A conferred increased protection to J774A.1 cells
against anthrax lethal toxin (LeTx) challenge compared to wild-
type sTEM8. To further evaluate the potency of L56A as an
anthrax toxin inhibitor compared with sTEM8 and sCMG2 we
prepared a new batch of proteins, repeated the cell protection
assay and used an improved Schild plot analysis to compare the
affinity of these constructs, as detailed in the experimental section.
All the constructs were soluble in the cytoplasm of Escherichia coli.
Without moving the His tag, there would be additional residues
(MSHHHHHHSM) at the N-termini of the recombinant proteins.
For all the purified proteins, only a single band was shown at a
lower molecular weight than expected on non-reducing polyacryl-
amide gels (Fig. 1A), suggesting that the redundancy did not
interfere with protein folding and the correct disulfide bond was
formed, as the crystal structures showed [17].
The protection assay yielded results consistent with our previous
study [17] with IC50 values of 274.668.7 nM, 69.565.8 nM, and
20.861.5 nM (Fig. 1B, Table 1) for sTEM8, L56A and sCMG2
respectively. sTEM8 and its more protective mutant L56A still
performed less efficiently than sCMG2. Accordingly, the Schild
plot analysis (Fig. 1C, Table 1) demonstrated that the sTEM8
mutant L56A elevated the affinity, with a Kd value 3.4 times lower
than that of sTEM8, consistent with our previous results obtained
by the BIAcore assays (29.8 nM for sTEM8 versus 4.44 nM for
L56A) [17]. However, the affinity of L56A was still lower than that
of sCMG2, with Kd values 11.1 times higher, confirming the
results of the protection assay.
L56A exhibits similar or slightly better protection than
sCMG2 in vivo
Based on the ability of these receptor decoys to inhibit PA
intoxication in vitro, we next tested the efficacy of sTEM8 and
L56A compared to sCMG2 in vivo. Cell-produced sCMG2 has
been reported to fully protect rats at a molar receptor: PA ratio of
between 1:1 and 2:1, whereas cell-produced sTEM8 could not do
so even at 15:1 [12]. In our studies, the bacterially-produced
sCMG2 exhibited similar efficacy (Table 2), conferring full
protection at receptor: PA ratios of 3:1 and 1:1, and significantly
increasing survival time at a ratio of 0.6:1 compared with the
LeTx-only group. Meanwhile, the bacterially-produced sTEM8
exhibited toxin inhibition superior to that of the reported cell-
produced sTEM8, conferring full protection at receptor: PA ratios
of 10:1 and 5:1, and protecting three of the six rats at a ratio of 3:1
(Table 2). This difference was consistent with the BIAcore results
(the prokaryote-expressed form has Kd values about 4 times lower
than the eukaryote-expressed form: 29.8 nM versus 130 nM
[17,18], without considering the system errors). The difference
between the two forms of sTEM8 may be ascribed to the different
expression systems applied (with or without glycosylation, for
example). As expected, the L56A mutant of sTEM8 performed
better than sTEM8, conferring full protection at receptor: PA
ratios of 3:1 and 1:1. Unexpectedly, however, L56A performed
similarly to or slightly better than sCMG2 (with prolonged survival
times of 115.369.660 min versus 91.6764.112 min, respectively,
at receptor: PA ratios of 0.6:1. P=0.0350, using the logrank test,
GraphPad Prism software, San Diego California USA) (Fig. 2,
Table 2).
sTEM8 and L56A bind to plasma proteins with slower
degradation rates than sCMG2 in vivo
sTEM8 and L56A had unexpectedly high efficacies in vivo. This
finding suggests that they may have pharmacokinetics that differs
from sCMG2. To address this hypothesis, we radiolabeled
sTEM8, L56A, and sCMG2 with Na
125I. Gel filtration monitored
by radiation was used to test the chromatographic behaviors of the
125I-labeled proteins and the corresponding serum samples from
rats after i.v. injection. The chromatography graphs are shown in
Fig. 3. The retention time of the scintillation peaks could be used
to estimate the size of the proteins (or their metabolites) with
labeled radioactivity. Generally, shorter retention times imply
increased molecular size caused by plasma protein binding, while
prolonged elution times imply degradation.
There were no significant differences between the behaviors of
the standard samples (
125I-labeled proteins loaded directly). The
three proteins all had single peaks with retention times slightly less
than 10 min. After being injected i.v. into rats, sTEM8 and L56A
exhibited comparable pharmacokinetics. The serum samples at
5 min showed only one peak, with a retention time of about
5 min. The clearly reduced retention times of the radiation peaks
indicates that sTEM8 and L56A could bind to plasma proteins to
form complexes with larger molecular weights. In contrast, a
serum sample at 5 min showed a single peak for sCMG2 that was
similar to that of its standard form, indicating a lack of plasma
protein binding.
For the serum samples at 30 min, sTEM8 and L56A both
showed two peaks: one with a retention time of about 5 min,
similar to that of the serum samples at 5 min, likely representing
the plasma protein binding complex, and another with a retention
time of slightly more than 10 min, probably representing degraded
metabolites. For sCMG2, only a single metabolite-peak with a
prolonged retention time was observed. Comparing this with the
chromatographic behaviors of the samples at 5 min suggests that
sCMG2 degraded much faster than sTEM8 and L56A (Fig. 3).
Pharmacokinetics of sTEM8, L56A, and sCMG2 indicate
that all three proteins exhibit fast rates of elimination
and extremely fast rates of distribution
The serum concentrations of
125I-sTEM8,
125I-L56A, and
125I-sCMG2 after i.v. injection at a 62.5 mg/kg dose were
monitored over time and are plotted in Fig. 4B. The serum
concentration profiles were fitted to a two-compartment model
(Fig. 4A), and the related fitted curves are depicted in Fig. 4B with
the corresponding pharmacokinetic parameters generated listed in
Fig. 4C.
All three proteins exhibited fast elimination rates and much
faster distribution rates, with an elimination half-life of less than
10 min and a distribution half-time of less than 1 min. For
distribution, all three proteins were assigned higher values for K12
than K21, indicating greater distribution in the second compart-
ment. The value of K12 for L56A was about 10-fold higher than
that for sTEM8 (222.60 h
21 versus 24.53 h
21, Fig. 4C), and value
TEM8 Based Anthrax Toxin Inhibitors
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21 versus 19.05 h
21,
Fig. 4C), resulting in a dominantly higher distribution for the peri-
compartment, as shown by values for Xc/Xp (0.14 versus 0.79,
Fig. 4C). Compared with sTEM8, sCMG2 exhibited about a 3.5-
fold higher K12 value (89.65 h
21 versus 24.53 h
21, Fig. 4C) but
about a 2.5-fold higher K21 (49.73 h
21 versus 19.05 h
21, Fig. 4C),
resulting in a slightly higher distribution ratio (0.56 versus 0.79,
Fig. 4C). The higher ratio for Xc/Xp implies that L56A and
sCMG2 are more likely than sTEM8 to remain in peri-
compartments (such as target organs) but not central compart-
Figure 1. Receptor variants can protect J774A.1 cells from LeTx intoxication. A. vWA domains of anthrax toxin receptors/variants were
fused with N-terminal His tags, purified by Ni affinity chromatography and anion exchange chromatography and analyzed with SDS-PAGE. B. The
results for cell protection assays. Viability was assessed as described in the methods section. Each assay was performed at least three times, with
duplicates within each assay. Data points represent the mean 6 SEM in duplicate for one representative experiment. C. The results for the Schild plot
assays; a, b, and c. PA dose-dependent survival curves for cells at a fixed receptor/mutant concentration; d, e, and f. These graphs were obtained by
plotting the EC50 values corresponding to different receptor concentrations, fixed by linear regression using GraphPad Prism software. Each assay was
performed at least three times. The data shown are for one representative experiment.
a Samples were not mixed with 2-mercaptoethanol.
doi:10.1371/journal.pone.0020646.g001
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their closer association with target organs contributes to their
better performance.
For elimination, L56A exhibited the largest Kdel value, which
was even larger than that of sCMG2. However, when associated
with the larger distribution rate K12, its elimination half-life was
averaged to approach that of sTEM8. sCMG2 exhibited an
elimination rate about 2.5-fold higher than sTEM8 (32.07 h
21
versus 13.38 h
21, Fig. 4C). When combined with its distribution
rates, sCMG2 exhibited an elimination half-life of 4.31 min, which
was about half that of sTEM8 (4.31 min versus 8.87 min, Fig. 4C).
Tissue distributions show that sTEM8 and L56A target to
the lungs, whereas sCMG2 targets to the kidney
To compare the distribution of sTEM8, L56A, and sCMG2 in
different tissues, TCA (Trichloroacetic Acid) sediments were
investigated 5 min, 30 min, and 4 h after i.v. administration of a
67.5 mg/kg dose (Figs. 5).
The results indicated that all three proteins had wide
distributions in tissues throughout the entire body within the time
course examined. Most of the tissues already had significantly
enriched TCA-precipitable radiations by 5 min after administra-
tion, especially the lung, liver, kidney, and spleen. This showed
maintenance of higher protein concentrations compared with the
serum, indicating a fast distribution rate for all three of the
proteins (Fig. 5).
sTEM8 and L56A presented similar organ-targeting for the
lung, which exhibited the highest observed concentrations:
332%, 375%, and 129% of the injected dose (ID) for sTEM8 at
5m i n , 3 0m i n , a n d 4h , r e s p e c t i v e l y ( F i g . 5 A ) , a n d 1 5 9 % ,
223%, and 19% for L56A (data sequenced) (Fig. 5B). By
comparison, the concentrations in serum were 143%, 67%, and
11% for sTEM8 and 47%, 20%, 6% for L56A (Figs. 5A & 5B).
When compared with other organs, the lung still received the
largest fraction (presented as relative distribution in Figs. 5D &
5E); the concentration of sTEM8 in the lung accounted for
28%, 51%, and 49% of the sum of the concentrations of all the
sampled tissues at 5 min, 30 min, and 4 h, respectively (Fig. 5D),
and 37%, 62%, and 17% for L56A (Fig. 5E). By comparison,
the relative distributions in the serum were 12%, 9%, and 4%
for sTEM8 and 11%, 5%, and 6% for L56A (Figs. 5D & 5E). At
all the sampled time points, the lung exhibited much higher
concentrations than the serum for both sTEM8 and L56A. For
sCMG2, the concentration in the lung was comparable to that
in the serum (Figs. 5C & 5F) at 5 min, and much less than was
found in the lung for sTEM8 and L56A, in terms of both the
absolute amount (%ID) and the relative distribution at 5 and
30 min.
By contrast, sCMG2 exhibited a completely different
distribution, targeting the kidney rather the lung: %ID values
for the kidney were 2310%, 235%, and 60% of the injected dose
(Fig. 5C), with relative distributions of 80%, 44%, and 19% at
5 min, 30 min, and 4 h, respectively. By comparison, %ID
values for serum were 57%, 10%, and 4%, with relative
distributions of 2%, 2%, and 1.2% (Fig. 5C). sTEM8 and L56A
did not show any significant pooling in the kidney compared
with the serum (Figs. 5A, 5B, 5D, & 5E), and the concentrations
and relative distributions were much lower than for sCMG2 at
all time points.
Table 1. Data results of the cell protection assay.
Receptor or mutant IC50 (nM), Mean ± SEM 1/slope
a
sTEM8 274.668.7 104.6612.56
L56A 69.565.8 31.7461.310
sCMG2 20.861.5 3.77460.2914
aReciprocal of the slope equals
kdm
kd
 
Rc ½  { PAR ½ 
PAR
z1, used for comparison of
the Kd values for receptors and mutants, as detailed in Supporting Information
S1. Data represent the mean 6 SEM values for three independent experiments.
doi:10.1371/journal.pone.0020646.t001
Table 2. In vivo protection against intoxication provided by different receptor decoys.
Experiment, treatment (molar ratio
a) No. of survivors/total Time to death (min) P
b
LeTx only
c 0/6 58/62/63/64/45/55
STEM8/LeTx:
10:1 3/3 NA
5:1 6/6 NA
3:1 3/6 126/106/83 0.0005
1:1 1/6 62/103/57/61/58 0.3230
L56A/LeTx:
3:1 3/3 NA
1:1 6/6 NA
0.6:1 0/6 155/112/129/94/92/110 0.0005
SCMG2/LeTx:
3:1 3/3 NA
1:1 6/6 NA
0.6:1 0/6 100/95/103/80/79/93 0.0005
NA, not applicable.
areceptor decoy:PA ratio when the latter is mixed with lethal toxin (LeTx).
bFor comparison with the LeTx-only control group, by logrank test.
cLeTx-only control group (50 mg of PA and 25 mg of LF per rat).
doi:10.1371/journal.pone.0020646.t002
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The comparable in vivo performance of L56A compared with
sCMG2 is unexpected, considering its clearly lower potency
observed in the in vitro assays (directly shown as IC50,
69.565.8 nM versus 20.861.5 nM), which was comparatively
consistent with the apparent affinity detected (displayed as 1/slope,
31.74 versus 3.78, Table 1). Moreover, considering that the results
of groups sTEM8/LeTX 3:1 and L56A/LeTx 0.6:1 did not show
significant differences (p=0.1514, logrank test, Fig. 2, Table 2),
the relative in vivo performance of L56A versus sTEM8 was
comparable to that in vitro (274.6 nM versus 69.5 nM, Table 1).
The discrepancy between the in vitro and in vivo efficacy of the
sTEM8-based decoys (sTEM8 and its mutant form L56A) and
sCMG2 imply that inconsistencies occur after i.v. administration.
The size exclusion HPLC-flow scintillation analysis showed that
sTEM8 and L56A exhibited an ability to bind plasma proteins,
whereas sCMG2 did not. The analysis also indicated that sCMG2
may disrupt faster in plasma. The greater than 90% plasma
protein binding for sTEM8 and L56A may be ascribed to their
negative charge, which is predicted to be about 26.10 at pH 7.0
and is supported by the chromatography strategy used, as implied
by the research on oligonucleotide pharmacokinetics [19]. By
comparison, sCMG2 carries a positive charge of about 1.37 and
did not bind to anion-exchange columns at near-neutral pH.
However, measurements of the dependence of plasma binding on
pH and ion strength are still needed to test this nonspecific binding
hypothesis, although specific receptor-ligand interactions in the
plasma seem unlikely [16,20].
Tissue distribution studies showed that sTEM8 and L56A
mainly target to the lung, whereas sCMG2 targets to the kidney
but not the lung. sTEM8 and L56A contain a lung-targeting GFE
motif, whereas sCMG2 contains a kidney-targeting DRG motif
[21,22], which may partially explain their differential targeting.
However, multiple factors may contribute to organ specific
distribution. For constructs with molecular weights of about
21 Kd, glomerular filtration in the kidney may be the main
pathway of elimination. Plasma-binding may help sTEM8 and
L56A escape this process to some extent. Certain receptor-ligand
interactions may also contribute to the distribution of sTEM8 and
its variant L56A. TEM8 is expressed in the respiratory epithelium
of the bronchi, especially in the ciliated epithelial cells surrounding
the luminal surface, the smooth muscle cells surrounding the
vessels, and the epithelial cells lining the alveoli but is only weakly
expressed in the endothelial cells lining the pulmonary vessels, as
determined by immuno-histochemistry in mice using an anti-
TEM8 polyclonal antibody that specifically recognizes the long-
form of TEM8 localized at the cell surface [23]. Immunohisto-
chemical studies have also shown the expression of CMG2 in the
epithelial cells lining the skin, colon, and lung and in the vascular
endothelium of these tissues in mice [24,25]. Further studies have
used real-time RT-PCR to show that both TEM8 and CMG2 are
expressed in the lung, with TEM8 being more highly-expressed,
but neither are expressed in the kidney [26]. Considering their
homology, TEM8 and CMG2 may also be expressed as cell
receptors in the lungs of rats. The concurrence between the target
organ and the organ-specific expression may imply that organ-
targeting may be receptor-ligand interaction dependent. This
assumes that the physical ligand would always be present near its
receptors. In the pharmacokinetic study, this receptor-ligand
interaction may result in some non-linear characteristics, which
may require further examination. The physiological functions of
TEM8 and CMG2 remain unclear. However, the vWA domain
of CMG2 has been reported to bind to basement-membrane
Figure 2. Receptor variants protect Rats from LeTx intoxication. Survival curves of rats protected by receptor decoys at different doses after
anthrax lethal toxin attack. Ratios indicate the receptor/decoy: PA ratio when the former was mixed with lethal toxin (LeTx). Rats were monitored for
3 h after i.v. administration and then overnight. For convenient comparison, groups with full protection are not shown and are listed in Table 2.
doi:10.1371/journal.pone.0020646.g002
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TEM8 binds to collagen I and gelatin [27]. These matrix proteins
are potential binding targets considering the reported co-
localization of CMG2 and collagen type IV [24]. However, they
cannot explain organ-specific pooling because they are distribut-
ed extensively throughout the body. sCMG2 appeared to be
incapable of lung-targeting, given that the spleen was the second
organ target and the lung did not show any enrichment
compared to other organs (Fig. 5). Given the conclusive evidence
that TEM8 and CMG2 are expressed as cell surface receptors in
the lungs of mice [23,24], the targeting of sTEM8 and L56A to
the lung may account for their superiority in protecting the lung
from anthrax toxin attack.
The pharmacokinetic parameters based on the drug concentra-
tion-time curve showed that all three proteins distributed and were
eliminated at a fast rate. The fast distribution rate constant a for
L56A is in accordance with its elevated affinity over sTEM8, which
supports the involvement of receptor-ligand interactions as a
mechanism contributing to their tissue distribution, given that they
share the same targeting motif and have only a single difference at
residue 56, which is distant from the GFE motif. In this way, this
hypothetical ligand may interact with the ATRs in much the same
Figure 3. Plasma protein binding of the receptor decoys in vivo. Rats were i.v. injected with
125I-L56A,
125I-sTEM8,
125I-sCMG2 at a dose of
67.5 g/kg via the tail vein (at volume 250 ml). The serum samples collected at 5 min, 30 min, and 4 h after dosing were analyzed by size exclusion
HPLC (TSK G3000 SWXL gel column)-flow scintillation analyzer (Radiomatic Model 600TRSeries, PerkinElmer, USA). For comparison, proteins labeled
with
125I were loaded directly on columns as standards. When compared with the peak of the standard, a faster peak implied plasma protein binding,
whereas a delayed peak may represent degraded protein.
doi:10.1371/journal.pone.0020646.g003
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a for sCMG2 is less than that for L56A, implying that sCMG2
exhibits a different mechanism for distribution or employs a
different receptor-ligand interaction that is much more difficult to
assess or has weaker binding. With regard to elimination, sTEM8
and L56A presented longer half-lives than did sCMG2, which may
be ascribed to the plasma protein binding that protects the
constructs from protease–mediated catalysis, and also to their tissue
Figure 4. Pharmacokinetics of the variants. A. Schematic diagram of the two-compartment model, which is generally used for protein drugs
administered i.v. by pulse injection. The two compartments are divided based on the different pharmacokinetic rates with the central compartment
(denoted as compartment 1) representing the vascular cavity and the peri-compartment (denoted as compartment 2) representing relatively
compact tissues. The elimination was limited in compartment 1 for simplification. The model can then be symbolized as C~A   e {at ðÞ zB   e {bt ðÞ . B.
Plasma concentration-time plots of receptor decoys after i.v. injection into rats (n=6) at a dose of 67.5 mg/kg. The point at time 0 was plotted based
on a deduced initial concentration of 105 ng/ml, which equaled the injection amount (13.5 mg for 200 g on average) divided by the theoretical
circulating blood volumes (12.8 ml for 200 g on average) [32]. Analysis applied the two-compartment model. Profiles are fitted by a two-phase
exponential decay equation (GraphPad Prism software, San Diego California USA) with constraints of a.1, b.1, and values shared. C. Related
pharmacokinetic parameters. Values for a, b were calculated by fitting plots in Fig. 4B with a two-phase exponential decay equation
Y~A   e {aX ðÞ zB   e {bX ðÞ zPlateau (GraphPad Prism software, San Diego California USA), with constraints of a.1, b.1, and values shared. Values
for half time were calculated as 0.69/a and 0.69/b. The first degradation rate constants were calculated by K21~
BazAb
AzB
, Kdel~
ab
K21
and
K12~azb{K21{Kdel. K21, and K12 represents the crossing rate between compartments, and Kdel represents the excretion rate out of the system, as
symbolized in figure 4A. XC/XP represents the ratio of drug amount distributed in the central compartment to that of the peri-compartment at
equilibrium, which equaled K21/K12.
doi:10.1371/journal.pone.0020646.g004
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the kidney, which may facilitate clearance from the body.
Overall, plasma protein binding and lung targeting seem to
confer superior efficacy to sTEM8 and L56A over sCMG2 in vivo,
which may explain why their performance approached that of
sCMG2 after i.v. administration, despite their inferior protection
in vitro.
The superiority of receptor-like decoys over antibody-based
antitoxins lies in their ability to accurately mimic the natural
receptor independent of natural or artificial changes in the toxin’s
amino acids, which would easily incapacitate the ability of site-
specific antibodies to block toxicity [14]. This characteristic
indicates that decoy design strategies should emphasize competi-
tion with the physical receptor, with equal consideration placed on
elevating affinity and improving target organ access. It has been
reported that PA, together with LF and EF, are all rapidly
degraded, with early localization of radioactivity in the liver,
spleen, and intestines and excretion through the kidneys [28].
However, for anthrax, present evidence indicates that the lung,
rather than the liver, is the organ that both expresses the relevant
toxin receptors and is the chief focus of infection and pathogenesis
[26,29]. It is possible that PA that distributes to target organs at a
dose under the level of detection may still be sufficient for
intoxication, which may emphasize the importance of co-
localizing decoys with the corresponding native receptors to block
the receptors and not just the toxin in circulation. sTEM8 and its
higher-affinity variant L56A, which is designed by homology
exchange to preserve the natural receptor’s character, could
effectively target the lung and confer protection to rats with a
performance approaching or even exceeding that of sCMG2. This
is extremely unexpected given their relatively lower affinities for
PA. However, their plasma residence times were still too short for
drug applications. Given that Fc-fusion strategies have been
applied to sCMG2, which effectively prolongs its half time while
preserving its decoy function, similar strategies may be explored to
develop prospective decoys based on sTEM8 or L56A with
Figure 5. Tissue distribution of the variants. TCA-precipitable radioactivity (mean 6SEM) in various tissues determined at 5 min, 30 min, and
4 h (n=6) after i.v. administration to rats. A, B, and C. %ID represents the equivalent drug concentrations calculated according to the radioactivity
measured as a percentage of the deduced injection dose (67.5 ug/kg). D, E, and F. Relative distribution represents the drug concentration in a certain
tissue as a percentage of the total drug concentration in all the tissues.
doi:10.1371/journal.pone.0020646.g005
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proved organ targeting in anthrax antitoxin research.
Materials and Methods
Plasmid construction, protein expression and purification
DNA fragments of the vWA domains of TEM8 (aa 38–220,
GenBank Accession Number AF421380; denoted as sTEM8) and
CMG2 (aa 38–218, GenBank Accession Number AY233452;
denoted as sCMG2) were amplified from cDNAs maintained in
our laboratory and cloned into PHAT vectors (EMBL, Heidel-
berg) between NcoI and BamHI sites with a six-His tag at the 59
end. Mutant L56A was obtained by inverse polymerase chain
reaction (PCR) using mutation-inducing primers at the base of
sTEM8 [17]. All clones were then validated by sequencing. In all
constructs, the Cys-Ala mutation (Cys 177 in TEM8 and Cys 175
in CMG2) was introduced to reduce dimer formation during
protein expression.
The constructs were expressed in BL21 (DE3) strains. After
growth for 4 h in 1 l of LB medium, the cell cultures were induced
with 0.4 mM IPTG for 16 h at 16uC. After ultrasonication, the
supernatants were separated using a Ni-affinity column (GE
Healthcare). sTEM8 and L56A were changed into Tris buffer
(pH 8.0) with 50 mM sodium chloride by ultrafiltration, after
which the target peaks were polished using a Source30Q column
(GE Healthcare). sCMG2 was changed into Tris buffer (pH 9.0)
containing 50 mM sodium chloride, and the peaks were directly
collected after being passed through a Source30Q column. Finally,
all proteins were concentrated and changed into Tris buffer
(pH 8.0) with 150 mM sodium chloride. The purity of the
recombinant proteins was analyzed by SDS-PAGE followed by
Coomassie Brilliant Blue staining. The protein concentrations
were then determined by the BCA Protein Assay (Thermo
Scientific, Rockford).
Cell protection assay and Schild plot analysis
Mouse macrophage J774A.1 cells were plated at 30,000 cells/
well in 96-well plates and cultured for 24 h before treatment. The
cells were then pre-cooled to 4uC to stop endocytosis. For the cell
protection assay, a dilution series of the constructs, combined with
PA and LF (final concentration of 100 ng/ml each), was added to
the cells to a final volume of 100 ml/well. For the Schild plot
analysis, a dilution series of PA combined with LF (final
concentration of 100 ng/ml) was added to the cells along with
different concentrations of the constructs. Next, the plates were
incubated at 4uC for 2 h for complete competition and then
transferred to 37uC. Cell viability was assayed 4 h after treatment
by replacing the medium with 100 ml of fresh medium (MEM plus
2% FBS) containing 1 mg/ml MTT (Invitrogen, USA). After 1 h
of incubation at 37uC, the medium was removed and the blue
pigment produced by the viable cells was dissolved in 50 ml/well of
0.5% (w/v) SDS and 25 mM hydrochloric acid in 90% (v/v)
isopropanol. The plates were then vortexed, and oxidized MTT
was measured as the absorbance at 570 nm using a Model 550
microplate reader (Bio-Rad, USA). Cell viability was calculated as
a percentage using the equation (ODmesured2ODdeath control)/
(ODlive control2ODdeath control), where ‘‘live control’’ wells contain
LF alone and ‘‘death control’’ wells contain both 100 ng/ml PA
and 100 ng/ml LF. IC50 or EC50 values were determined by
nonlinear regression sigmoidal dose-response analysis with vari-
able slopes (Prism, version 4.0; GraphPad, USA). Each assay was
performed at least three times, with duplicates within each assay.
The model used to fit the probable mathematical relationship
between affinity and inhibition concentration is detailed in
Supporting Information S1.
Anthrax lethal toxin (LeTx) challenge in rats
In vivo experiments with animals were performed according to
previously published methods [30]. All experiments were ap-
proved by the Animal Care and Use Committee of the Beijing
Institute of Microbiology and Epidemiology (permit numbers:
20100701 and 20101101). Male Fisher 344 rats (Vital River,
China) weighing 200–250 g were challenged with LeTx (50 mgP A
mixed with 25 mg LF to a final volume of 500 ml in PBS per rat)
via the tail vein. For rats that received receptors or mutants,
decoys were also added to LeTx to a final volume of 500 ml, and
the resultant solution was co-injected into the rats. The rats were
then monitored for intoxication symptoms and death. Statistical
analysis was conducted using the logrank test (Prism, version 4.0).
Radio iodination and purification of
125I-sTEM8,
125I-L56A
and
125I-sCMG2
Iodogen (1,3,4,6-tetrchloro-3a,6a-diphenylglycoluril) and
Na
125I solutions were obtained from Sigma Chemical Co. (St.
Louis, MO, USA) and Perkin Elmer Life Sciences Inc. (Boston,
MA, USA), respectively. sTEM8, L56A, and sCMG2 contain
several tyrosine residues that enable them to be
125I-labeled [31].
sTEM8, L56A, and sCMG2 were radiolabeled with Na
125I using
the Iodo-Gen method as described in the manual. Briefly, 1 ml of
each protein (2 mg/ml) was incubated with 50 mlo fN a
125I
(5 mCi) in a reaction tube coated with 100 mg of iodogen at room
temperature with gentle stirring for 10 min. The incubation was
stopped by the addition of PBS (20 mM, pH 7.4). After
incubation, to separate free
125I from the protein-bound
125I, the
iodinated protein was purified on a Sephacyl
TM S-200 high-
resolution column (1 cm640 cm) by eluting with PBS (20 mM,
pH 7.4) at a flow rate of 1 ml/min. The effluents were collected at
1-min intervals. Through radioactivity determination, the fractions
containing
125I-labeled protein were collected, and the remaining
fractions were discarded. Under size exclusion chromatography
conditions,
125I-sTEM8,
125I-L56A, and
125I-sCMG2 were all
eluted between 9 to 12 min, whereas free
125I was eluted between
16 to 18 min after injection. The radiochemical purity of the
125I-
labeled protein was confirmed to be greater than 95% as
determined by HPLC. The proteins labeled with
125I had a
specific activity of 198.19 kBq/mg for sTEM8, 141.23 kBq/mg for
L56A and 56.67 kBq/mg for sCMG2.
Validation of radioactivity determination in serum, urine,
and tissues by TCA precipitation assay
Precipitation of the iodinated proteins in the plasma and tissues by
ice-cold 10% TCA was used to remove free
125Io r
125I associated
with the fragmented peptides. Hence, TCA-precipitable radioactivity
rather than total radioactivity was used to calculate the
125I-protein
concentration in rat serum and tissue homogenate samples. A series
of calibration standards were prepared by adding five concentrations
of 0.045–11.528 mg/ml for
125I-L56A, 0.054–33.7 mg/ml for
sTEM8, and 0.03–16.08 mg/ml for sCMG2 into the blank serum,
tissue and urine samples that were examined. The relationship
between the added concentrations and measured radioactivity of the
standards was evaluated. The results showed good relationships
(r
2.0.99) and recovery (.80%) for the entire matrix.
Pharmacokinetic studies
Rats (n=6, 200620 g) were i.v. injected with
125I-L56A,
125I-
sTEM8, and
125I-sCMG2 at a dose of 67.5 g/kg via the tail vein
TEM8 Based Anthrax Toxin Inhibitors
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were collected from the tail vein at 0, 5, 10, 20 min, and 0.5, 1, 2,
and 4 h from the same rat and then centrifuged at 3000 g for
10 min. Serum samples at 5 min, 30 min, and 4 h after dosing
were analyzed by size exclusion HPLC (TSK G3000 SWXL gel
column, 300 A ˚,1 0 mm, 7.8 mm6300 mm)-flow scintillation
analyzer (Radiomatic Model 600TRSeries, PerkinElmer, USA)
to investigate the metabolism of each protein in vivo.
125I-protein-associated radioactivity in the serum samples was
determined after precipitation with TCA (10%, v/v). Briefly, each
serum aliquot (50 ml) was added to 0.4 ml of ice-cold TCA (10%,
v/v), vortex-mixed, and incubated on ice for 30 min. The mixture
was then centrifuged at 16,0006ga t4 uC for 10 min, and the
supernatant, containing free
125Io r
125I associated with fragment-
ed peptide, was aspirated from each sample. The resultant TCA
precipitate was then counted using a gamma counter (2470-005,
WIZARDTM PerkinElmer, Finland) to determine the amount of
125I radioactivity that remained associated with precipitable
protein. The result of
125I-labeled protein concentration in each
time point was expressed as nanogram equiv. per milliliter
(ng?equ?mL
21). A two-department model was applied, and the
data were fitted using a two-phase exponential decay equation
(GraphPad Prism software, San Diego California USA) with
constraints of a.1, b.1, and values shared.
Tissue distribution of
125I-L56A,
125I-sTEM8, and
125I-
sCMG2
Three groups of rats (n=6 per group) were i.v. injected at a
single dose of 67.5 g/kg in the same manner as described above.
The rats in the three groups were sacrificed by decapitation at
5 min, 0.5, and 4 h post-dosing, and blood and urine samples
(300–400 ml) were immediately collected. Blood aliquots were
immediately processed, and the resultant serum samples were
analyzed as described. The tissues or organs including the heart,
lung, liver, spleen, kidney, bladder, testis, jejunum, adipose, muscle
and brain were excised, trimmed of extraneous fat, residual muscle
and connective tissue, thoroughly rinsed of residual blood or
contents with ice-cold 20 mM PBS (pH 7.4), and blotted dry. For
radioactivity assays, small slices of tissues/organs were individually
weighed, recorded and immediately homogenized twice at
8000 rpm for 30 s each time in 400 ml of ice-cold TCA (10%,
v/v). The homogenates were then centrifuged at 3000 rpm for
10 min at 4uC, and the pellet was used for counting in the gamma
counter.
Supporting Information
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